PD6-3-5: Pharmacoeconomic analysis shows that erlotinib is...

PD6-3-5: Pharmacoeconomic analysis shows that erlotinib is cost-saving versus docetaxel, and cost-effective versus best supportive care (BSC) in NSCLC

Pompen, Marjolein, Novak, Annoesjka, Gok, Murat, Gyldmark, Marlene, Postmus, Pieter, Afram, Charles
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
2
Language:
english
Journal:
Journal of Thoracic Oncology
DOI:
10.1097/01.JTO.0000283343.74967.96
Date:
August, 2007
File:
PDF, 164 KB
english, 2007
Conversion to is in progress
Conversion to is failed